Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Article Details

Citation

Copy to clipboard

Ghosh AK, Dawson ZL, Mitsuya H

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Bioorg Med Chem. 2007 Dec 15;15(24):7576-80. Epub 2007 Sep 14.

PubMed ID

17900913 [ View in PubMed

]

Abstract

Our structure-based design strategies which specifically target the HIV-1 protease backbone, resulted in a number of exceedingly potent nonpeptidyl inhibitors. One of these inhibitors, darunavir (TMC114), contains a privileged, structure-based designed high-affinity P2 ligand, 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF). Darunavir has recently been approved for the treatment of HIV/AIDS patients harboring multidrug-resistant HIV-1 variants that do not respond to previously existing HAART regimens.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Darunavir	Human immunodeficiency virus type 1 protease	Protein	Human immunodeficiency virus 1	Yes	Inhibitor	Details